



Rev Panam Salud Publica. 2018; 42: e165.

PMCID: PMC6386160

Published online 2018 Oct 10. doi: 10.26633/RPSP.2018.165: 10.26633/RPSP.2018.165

PMID: [31093193](#)

Language: English | [Spanish](#) | [Portuguese](#)

Mental health in the Americas: an overview of the treatment gap

[Robert Kohn](#),¹ [Ali Ahsan Ali](#),² [Victor Puac-Polanco](#),³ [Chantal Figueroa](#),⁴ [Victor López-Soto](#),⁵ [Kristen Morgan](#),⁶ [Sandra Saldivia](#),⁷ and [Benjamín Vicente](#)⁷

¹ Department of Psychiatry and Human Behavior, Brown University, Providence, Rhode Island, United States of America.

² Department of Psychiatry, Icahn School of Medicine at Mount Sinai, Elmhurst Hospital Center, New York, New York, United States.

³ Department of Epidemiology, Columbia University, New York, New York, United States.

⁴ Global Health Program, Colorado College, Colorado Springs, Colorado, United States.

⁵ Independent Researcher, Guatemala City, Guatemala.

⁶ Brown University School of Public Health, Providence, Rhode Island, United States.

⁷ Department of Psychiatry and Mental Health, University of Concepción, Concepción, Región del Bío Bío, Chile.

Send correspondence to Robert_Kohn@brown.edu

Conflict of interests. None declared.

Received 2018 May 3; Accepted 2018 Aug 17.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 3.0 IGO License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited. No modifications or commercial use of this article are permitted. In any reproduction of this article there should not be any suggestion that PAHO or this article endorse any specific organization or products. The use of the PAHO logo is not permitted. This notice should be preserved along with the article's original URL.

ABSTRACT

Objective

To understand the mental health treatment gap in the Region of the Americas by examining the prevalence of mental health disorders, use of mental health services, and the global burden of disease.

Methods

Data from community-based surveys of mental disorders in Argentina, Brazil, Canada, Chile, Colombia, Guatemala, Mexico, Peru, and the United States were utilized. The World Mental Health Survey published data were used to estimate the treatment gap. For Canada, Chile, and Guatemala, the treatment gap was calculated from data files. The mean, median, and weighted treatment gap, and the 12-month prevalence by severity and category of mental disorder were estimated for the general adult, child-adolescent, and indigenous populations. Disability-adjusted Life Years and Years Lived with Disability were calculated from the Global Burden of Disease study.

Results

Mental and substance use disorders accounted for 10.5% of the global burden of disease in the Americas. The 12-month prevalence rate of severe mental disorders ranged from 2% – 10% across studies. The weighted mean treatment gap in the Americas for moderate to severe disorders was 65.7%; North America, 53.2%; Latin America, 74.7%; Mesoamerica, 78.7%; and South America, 73.1%. The treatment gap for severe mental disorders in children and adolescents was over 50%. One-third of the indigenous population in the United States and 80% in Latin America had not received treatment.

Conclusion

The treatment gap for mental health remains a public health concern. A high proportion of adults, children, and indigenous individuals with serious mental illness remains untreated. The result is an elevated prevalence of mental disorders and global burden of disease.

Keywords: Mental disorders, professional practice gaps, mental health services, Americas

Disparities in the prevention, care, and rehabilitation of mental disorders in the Americas is a growing public health problem. Addressing the growing burden of mental disorders requires an understanding of the prevalence, the associated burden of disease, and the treatment gap for these disorders. The global burden of mental disorders, among other factors, is associated with the high prevalence of mental disorders, the early onset of mental disorders, and the wide treatment gap ([1](#), [2](#)).

Reducing the treatment gap and the 12-month prevalence of mental disorders is the primary modifiable factor in diminishing the global burden of mental disorders and its societal impact. Consequences of failure to reduce the treatment gap include low educational attainment, reduced motivation to work, difficulties in work performance, impairments in personal function, discrimination that reduces occupational attainment, and lower income attainment ([3](#), [4](#)). Mental disorders are also associated with increases in poverty, impaired family function, teen pregnancy, domestic violence, poorer quality of life, and mortality beyond that due to suicide ([5](#) – [9](#)). In the Americas, as elsewhere in the world, only a minority of individuals with mental disorders have received treatment in the preceding year, and initial treatment contact is frequently delayed for many years ([10](#), [11](#)).

Although research on the epidemiology of mental disorders in Latin America has been concentrated primarily in a few countries, advances have been made in the last decade (12). There has been an increasing number of studies on the prevalence of mental illness in the community, with data on service utilization. In addition, studies on the rates of mental illness in children, adolescents, and indigenous populations have been conducted. Research initiatives, such as the Global Burden of Disease Study (13), the World Mental Health Surveys (14), the Mental Health Atlas (15, 16), and the WHO Assessment Instrument for Mental Health Systems (WHO-AIMS; 17) have provided a better understanding of the prevalence, burden, and treatment gap in the Americas.

The objective of this report was to understand the extent of the mental health treatment gap in the Region of the Americas by examining the prevalence of mental health disorders, use of mental health services, and the global burden of disease in the region.

MATERIALS AND METHODS

The Global Burden of Disease Study 2016 (GBD 2016) was used to estimate the proportion of disease burden that came from mental and substance use disorders (18). Data from the Institute of Health Metrics and Evaluation (19) was obtained for each country in the Americas by specific disorder, age, and gender. GBD 2016 estimates for Disability Adjusted Life Year (DALY) and Years Lived with Disability (YLD) were determined for the Region of the Americas as a whole (including the Caribbean, Latin America, and North America). These were compared to global estimates. In addition, estimates were made by subregion: North America (Canada and the United States); Mesoamerica (Costa Rica, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, and Panama); the Latin Caribbean (Cuba, Dominican Republic, Haiti, and Puerto Rico); South America (Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Paraguay, Peru, Uruguay, and Venezuela); and the non-Latin Caribbean (Antigua and Barbuda, Bahamas, Barbados, Belize, Bermuda, Dominica, Jamaica, Saint Lucia, Saint Vincent and the Grenadines, Grenada, Guyana, Suriname, Trinidad and Tobago, United States Virgin Islands).

Studies on a 12-month prevalence of mental disorders were selected based on being the most representative community-based survey of a country—using the Composite International Diagnostic Interview (CIDI; 20), the Diagnostic Interview Schedule for Children (DISC; 21), or a latter equivalent interview schedule—and having available service utilization data to permit calculation of the treatment gap. The studies, therefore, were not necessarily a country's most recent mental health prevalence survey. Data from studies that were part of the World Mental Health Survey (WMHS) were obtained from published reports: Argentina (22), $n = 3\,927$, age ≥ 18 years, was based on a nationally representative sample; Brazil (23), $n = 5\,037$, age ≥ 18 years, collected data from metropolitan São Paulo; Colombia (24), $n = 4\,426$, age 18 – 65 years, included all urban areas; Mexico (25), $n = 5\,782$, age 18 – 65 years, included all urban areas; Peru (26), $n = 3\,930$, age 18 – 56 years, was based on five urban areas; and the United States (27), $n = 9\,282$, age ≥ 18 years, was a nationally representative sample from its National Comorbidity Survey Replication. The study selected for Canada (28), $n = 38\,492$, age ≥ 15 years, was representative of much of the country and used the WMHS CIDI. For Chile (29), $n = 2\,978$, age ≥ 15 years, a CIDI 1.1 survey of four provinces represented the major geographic areas and used the Diagnostic and Statistical Manual of Mental Disorders, 3rd edition, revised (DSM-III-R) rather than DSM-IV. For Guatemala (30), $n = 1\,452$, age

18 – 65 years, a nationally representative survey used the CIDI 2.1 and sampled all the ethnic groups in the country, including the Ladino (mixed indigenous and European heritage, but identifying as non-indigenous) and the Maya (encompassing 21 different ethnicities) populations.

If the information was not readily presented in a table, it was extrapolated from the data presented in the reports. For Canada (28), Chile (29), and Guatemala (30), the data files were obtained from the investigators (Canada public domain) and analyzed with SUDAAN (Research Triangle Institute, Raleigh, North Carolina, United States) using the appropriate weights to account for the national census and the sample design. The 12-month treatment rate was used for all countries except Chile, which used a 6-month rate. Severity of mental disorders for the WMHS was based on the Sheehan Disability Scale (31). For Canada, Chile, and Guatemala, the severity of mental disorders was rated with an index based on the diagnosis and the extent of comorbidity (29, 32). Estimates of the treatment gap for the Americas and subregions were calculated by the mean and median across studies, as well as a weighted mean. The weighted average took into account each country's population (1); unlike the mean and median estimates, which did not distinguish among countries based on population size. In addition, the weighted 12-month prevalence of those without treatment by subregion was estimated.

Treatment gaps were also examined for children and adolescents and the indigenous population. For the Chile study ($n = 1\,558$, age 4 – 18 years), based on four provinces representing all major geographic areas, parents were interviewed on behalf of children 4 – 11 years of age; only the adolescent was interviewed in the group 12 – 18 years of age; and severity of disorders was based on the DISC severity criteria (33, 34). In the Puerto Rico study ($n = 1\,886$, age 4 – 17 years), a nationally representative sample, both child and parent were interviewed and the Children's Global Assessment Scale (CGAS; 35, 36) was used. In the two CIDI-Adolescent Supplement studies in Mexico ($n = 3\,005$, age 12 – 17 years) and the United States ($n = 10\,123$, age 13 – 18 years), only the adolescent was interviewed (37 – 39). Severity of mental disorders was measured using the Sheehan Disability Scale in Mexico (37) and the CGAS in the United States (38, 39). The Mexico survey was limited to Mexico City. The nationally representative study of the United States used lifetime service utilization (40), while the other studies were based on 12-month service utilization. The 12-month prevalence rates were used for all of the child and adolescent studies.

Studies providing prevalence and service utilization of indigenous populations in the Americas were obtained from Chile ($n = 75$, age ≥ 15 years; 43), Guatemala ($n = 409$, age 15 – 65 years; 30), and the United States (41, 42)—based on a study of two indigenous tribal groups ($n = 3\,084$, age 15 – 54 years) and a nationally representative sample of American Indians and Alaska natives ($n = 701$, age ≥ 18 years). DSM-IV and the 12-month treatment rates were used in all, except Chile which used DSM-III-R and a 6-month treatment rate. The 12-month prevalence rates were used for each of the studies. The data presented on the Mapuche in Chile (43) and the Maya in Guatemala was obtained from analysis of data files provided by the investigators.

RESULTS

Global burden of mental disorders

Mental and substance use disorders account for 10.5% of the DALYs in the Americas ([Table 1](#)). Among children, 5.2% of all DALYs are due to mental and substance use disorders, whereas among those 15 – 59 years of age, the rate is 16.6%. Mental health and substance use disorders account for 22.0% of YLDs in the Americas and 28.5% among those 15 – 59 years of age. North America has a markedly higher GBD associated with mental health and substance use disorders than does Latin America and the Caribbean (LAC).

Among those 15 – 59 years of age, there were notable differences in DALYs and YLDs between North America and LAC: DALYs for schizophrenia were 1.3 versus 0.9; alcohol use disorders, 2.0 versus 2.1; drug use disorders, 7.7 versus 1.7; depressive disorders, 4.8 versus 3.0; bipolar disorders, 0.9 versus 1.2; and anxiety disorders, 3.0 versus 2.4. The YLDs for schizophrenia were 2.2 versus 1.8; alcohol use disorders, 2.2 versus 3.0; drug use disorders, 8.2 versus 2.5; depressive disorders, 8.5 versus 6.4; bipolar disorders, 1.6 versus 2.6; and anxiety disorders, 5.2 versus 5.1.

Prevalence of mental disorders

The prevalence of mental disorders across the Americas varies considerably depending on the study: the 12-month prevalence range ranged from 7.2% in Guatemala to 29.6% in Brazil. The rate of severe mental disorders ranged from 2.0% in Guatemala to 10.0% in Brazil ([Table 2](#)). The weighted mean 12-month prevalence of mental disorders in the Americas was 17.0%; North America, 22.5%; Latin America, 14.8%; Mesoamerica, 9.7%; and South America, 17.0%. [Table 3](#) presents the rates by subregions for anxiety, affective, and substance use disorders and by severity.

Treatment gap

A summary of mental health services utilization by type of provider is presented in [Table 4](#). The weighted mean for the treatment gap in the Americas for any mental disorder was 71.2%; for severe disorders, 57.6%; and for severe to moderate disorders, 65.7%. The treatment gap for severe mental disorders in North America was 40.5%; Latin America, 69.9%; Mesoamerica, 77.4%; and South America, 66.8%. For severe to moderate disorders, the treatment gap increased substantially; North America, 53.2%; Latin America, 74.7%; Mesoamerica, 78.7%; and South America, 73.1% ([Table 5](#)). Substance use disorders had the highest treatment gap in the Americas. In Latin America, the treatment gap for substance use disorders was 83.7% compared to 69.1% for North America. The treatment gap for anxiety disorders ranged from 56.2% in North America to 81.8% in Mesoamerica. For affective disorders, the treatment gap was 58.4% in North America and 77.4% in Mesoamerica.

Mental disorders are highly prevalent among children and adolescents: 16.2% in Puerto Rico, 38.3% in Chile, 39.4% in Mexico, and 42.6% in the United States. The treatment gap for children and adolescents was over 64% in Puerto Rico and the United States; over 66% in Chile; and over 86% in Mexico. Severe mental disorders in children and adolescents had a treatment gap over 50%: Chile, 59.4%; Mexico, 80.8%; Puerto Rico, 50.4%; and the United States, 52.6%.

Among the indigenous population in the United States, approximately one-third of those with a mental disorder had not received treatment. In Chile and Guatemala, the treatment gap was markedly higher—over 80%. Use of traditional healers was low in the Latin American studies, 0% among the Mapuche in Chile and 8.2% among the Maya in Guatemala. In the United States, among the two tribes studied, 19% – 39% with mental disorders utilized a traditional healer.

DISCUSSION

The treatment gap for adults remains wide throughout the Americas. It is much larger in Latin America, but still unacceptably high in North America. Despite the lower treatment gap in North America, the global burden of disease for mental health is higher comparatively, which may reflect the elevated prevalence of mental disorders in North America. When the prevalence of mental disorders is taken into account, the treatment gap for North America begins to approach that of Latin America. The weighted 12-month prevalence treatment gap for substance use disorders in North America exceeds that of Latin America; however, the prevalence for severe disorders remains markedly lower.

The treatment gap is illustrated by the wide disparities in mental health resources for adults across countries in the Americas. For example, the mental health workforce per 100 000 population in Mesoamerica is 8.7; in the non-Latin Caribbean, 69.2; South America, 8.7; and the United States, 125.2 (15). Overall, in the Americas, the mental health workforce per 100 000 is 10.9 (16). The median rate of beds in mental hospitals per 100 000 in the Americas is 16.7; Mesoamerica, 3.9; the non-Latin Caribbean, 75.3; South America, 9.0; and the United States, 23.6. The median rate of psychiatric beds in general hospitals per 100 000 in the Americas is 1.7; in Mesoamerica, 0.2; the non-Latin Caribbean, 4.7; South America, 0.3; and the United States, 11.5. The median rate of community residential facility beds per 100 000 in Mesoamerica is 0; the non-Latin Caribbean, 2.8; South America, 0.8; and the United States, 15.2. Access to basic medications remains an issue in some countries of Latin America; for example, in Peru antidepressants and antipsychotics were available in about two-thirds of hospitals and less than 20% of health centers and small health clinics (44).

The treatment gap for children and adolescents across the Americas is alarming, ranging from 64% – 86%. The need to address mental health services and improve access to care for children has received little attention. A report from Mexico highlights the issues facing Latin America (45). The infrastructure for child mental health care is lacking in both material and workforce resources, in particular, a lack of child psychiatrists and training programs for child and adolescent mental health providers. Primary care providers have no training to detect mental disorders in children. Furthermore, mental health services in Mexico are delivered through an underfunded, under-resourced, and uncoordinated network of institutional providers isolated from the larger health care system.

The indigenous population in Latin America, although only represented by two studies (one of which was a small sample survey), highlight a marked difference in the treatment gap with the general population. The needs of the indigenous population, however, do not differ from the non-indigenous (46).

Countries in Latin America have invested less in mental health care compared to other subregions and countries of similar income (47). Key factors that have continued to impede improving mental care, decreasing the treatment gap, and reducing the global burden of disease include weak political will to implement reforms; a low allocation of health budgets to mental health; absence of legislation to protect the human rights of people with mental disorders; the persistence of inappropriate, but costly systems of hospital care; and a slow shift in investment from a mental hospital-model to community model (47). In addition, there are individual barriers to care, such as the belief that the problem will resolve on its own or that the individual can solve the problem, stigma, lack of mental health literacy, financial burdens, lack of trust in the health care system, and the belief that treatment is not helpful.

The Pan American Health Organization, Regional Office of the World Health Organization for the Americas (PAHO/WHO) has identified five strategic areas (48) to address the treatment gap:

- i. Development and implementation of national mental health policies, plans, and laws;
- ii. Promotion of mental health and prevention of psychological disorders, with emphasis on the psychosocial development of children;
- iii. Primary health care-centered mental health services delivery;
- iv. Human resources development; and
- v. Strengthening capacity to produce, assess, and use information on mental health.

WHO has developed targets for countries by the year 2020 (49):

- 80% will have developed or updated their policies/plans for mental health in line with international and regional human rights instruments.
- 50% will have developed or updated their laws for mental health in line with international and regional human rights instruments.
- Service coverage for severe mental disorders will have increased by 20%.
- 80% will have at least two functioning national, multisectoral promotion, and prevention programs in mental health.
- The rate of suicide in countries will be reduced by 10%.
- 80% will routinely collect and report at least a core set of mental health indicators every 2 years through their national health and social information systems.

A recent review focused on Latin America and the Caribbean suggested (50):

- Creating a larger consensus among stakeholders to improve mental health care;
- Having users and families participate in policy and service development;
- Increasing funding allocated to mental health;
- Strengthening research capacity and, in particular, for evidence-based mental health reforms;
- Increasing and improving the public health capacity of mental health leaders;
- Strengthening the capacity of the ministries of health in implementing mental health policy;
- Promoting international cooperation in capacity building, research, and policy development. In addition, outpatient mental health care needs to be decentralized;

- Collaborative mental health care integrated with primary care needs developing and expansion;
- Primary child and indigenous mental health needs to be prioritized; and
- National mental health information systems need to be developed and strengthened.

Progress in reducing the mental health treatment gap in the Americas has been slow. In Latin America, the lack of financing and political will have prevented the scaling up of mental health, which has resulted in integrated care, community mental health, and psychosocial rehabilitation not being successfully implemented in the Region on a large scale (51). There are a number of examples, however, of programs that were developed to integrate mental health with community care in Argentina, Belize, Brazil, Chile, Cuba, Jamaica, and Mexico (52); some of these programs have undergone rigorous evaluation, but not all. The Chile National Depression Treatment Program in primary care is touted as a model (53).

One of the more notable programs has been the Mental Health Gap Action Program (mh-Gap). The mh-Gap aims to reduce the treatment gap by scaling up mental health care in primary care settings and capacitating primary care providers (PCPs) to become the gateway to mental health care. Additionally, an mhGap goal is to reduce barriers to mental health care in the primary health care settings by scaling up PCPs' knowledge. Well-designed controlled studies of mhGap in the Americas are needed, particularly given the failure of other initiatives to train PCPs to provide mental health care in the Region (54).

To be successful, interventions should be customizable, transportable to different settings, and have a delineated process for knowledge transfer. As changes at the different levels of the mental health systems are implemented, outcome measures need to be included as quality indicators. For example, repeating the WHO-AIMS at specific intervals could be used as a measure of progress. Quality indicators measured at the local level and at the Ministry of Health level need to be established and implemented. At the national level, mental health indicators that could be monitored for adult, children, indigenous populations, and the severely mentally ill include: the number of beds dedicated to mental hospitals, general hospital psychiatric units, day programs, and rehabilitation programs, in both the private as well as the public sector; the rate of involuntary hospitalizations; length of stay in mental hospitals and psychiatric units in general hospital; primary care treatment of mental illness; human resources; and expenditures for mental health. Mental health indicators for clinicians have been developed and also should be monitored as the mental health systems in countries are strengthened.

Limitations

The data presented are estimates of prevalence and the treatment gap for the Region of the Americas. Data were available only on a few countries in Latin America, and none of the non-Latin Caribbean. In North America, both the United States and Canada were represented. A similar methodology was used for each of the prevalence studies; yet, there are marked differences in the rates of prevalence. Methodological issues cannot be fully dismissed. The Chile study is older than the others, and data on treatment seeking was based on 6 not 12 months, which may have over-estimated that country's treatment gap. A more recent study in Chile (55) found that 21.2% were treated with antidepressants in the past year, suggesting that the older study over-estimated the

gap. The three different estimates of the treatment gap presented (mean, median, and weighted) illustrate that countries in the same subregion differ in treatment gap. It is not fully clear whether these estimates would remain relatively similar if all of the countries of the Americas were included.

Conclusions

The mental health treatment gap in the Americas is a public health priority. A high proportion of adults, children, and indigenous individuals with serious mental illness remains untreated. The global burden of mental health and the prevalence of mental illness are high, and in part, reflect the treatment gap.

A metric that is not available in these studies, one that could be used to measure progress in subsequent national, psychiatric, epidemiological studies, is the number of those in treatment who no longer meet criteria for 12-month prevalence, but who have had a lifetime prevalent disorder. As mental disorders are often chronic, a rise in this remission metric would illustrate success in reducing the treatment gap.

Although concerted efforts are being made at the local level to address the treatment gap by scaling up and task-shifting overall, with a few exceptions there has been little progress. Mental health should be a priority at the national level across the Americas. Verifiable quality indicators are needed to demonstrate progress.

Funding Statement

Victor Puac-Polanco is supported in part by grant R49CE002096 (PI: Li, G) from the United States Centers for Disease Control and Prevention. The funder had no role in the study design, data collection, or analysis, decision to publish, or preparation of the manuscript.

Footnotes

Suggested citation Kohn R, Ali A, Puac-Polanco V, Figueroa C, López-Soto V, Morgan K, et al. Mental health in the Americas: an overview of the treatment gap. *Rev Panam Salud Publica*. 2018;42:e165.

<https://doi.org/10.26633/RPSP.2018.165>

Funding. Victor Puac-Polanco is supported in part by grant R49CE002096 (PI: Li, G) from the United States Centers for Disease Control and Prevention. The funder had no role in the study design, data collection, or analysis, decision to publish, or preparation of the manuscript.

Disclaimer. Authors hold sole responsibility for the views expressed in the manuscript, which may not necessarily reflect the opinion or policy of the *RPSP/PAJPH* and/or PAHO.

REFERENCES

1. Kohn R, Saxena S, Levav I, Saraceno B. The treatment gap in mental health care. *Bull World Health Organ*. 2004;82(11):858–866. doi: /S0042–96862004001100011. [PMCID: PMC2623050] [PubMed: 15640922]
2. Kohn R. Trends and gaps in mental health disparities. In: Okpaku SO, editor. *Global mental health: essential concepts*. New York: Cambridge University Press; 2014.
3. Alonso J, Petukhova M, Vilagut G, Chatterji S, Heeringa S, Üstün TB, et al. Days out of role due to common physical and mental conditions: results from the WHO World Mental Health surveys. *Mol Psychiatry*. 2011;16(12):1234–1246. doi: 10.1038/mp.2010.101. [PMCID: PMC3223313] [PubMed: 20938433] [CrossRef: 10.1038/mp.2010.101]
4. Kawakami N, Abdulghani EA, Alonso J, Bromet EJ, Bruffaerts R, Caldas-de-Almeida JM, et al. Early-life mental disorders and adult household income in the World Mental Health Surveys. *Biol Psychiatry*. 2012;72(3):228–237. doi: 10.1016/j.biopsych.2012.03.009. [PMCID: PMC3402018] [PubMed: 22521149] [CrossRef: 10.1016/j.biopsych.2012.03.009]
5. Davidson LL, Grigorenko EL, Boivin MJ, Rapa E, Stein A. A focus on adolescence to reduce neurological, mental health and substance-use disability. *Nature*. 2015;527(7578):S161–S166. doi: 10.1038/nature16030. [PubMed: 26580322] [CrossRef: 10.1038/nature16030]
6. Baxter AJ, Harris MG, Khatib Y, Brugha TS, Bien H, Bhui K. Reducing excess mortality due to chronic disease in people with severe mental illness: meta-review of health interventions. *Br J Psychiatry*. 2016;208(4):322–329. doi: 10.1192/bjp.bp.115.163170. [PubMed: 26941263] [CrossRef: 10.1192/bjp.bp.115.163170]
7. Laursen TM, Musliner KL, Benros ME, Vestergaard M, Munk-Olsen T. Mortality and life expectancy in persons with severe unipolar depression. *J Affect Disord*. 2016;193:203–207. doi: 10.1016/j.jad.2015.12.067. [PubMed: 26773921] [CrossRef: 10.1016/j.jad.2015.12.067]
8. Zlotnick C, Johnson J, Kohn R, Vicente B, Rioseco P, Saldivia S. Childhood trauma, trauma in adulthood and psychiatric diagnoses: results from a community sample. *Compr Psychiatry*. 2008;49(2):163–169. doi: 10.1016/j.comppsy.2007.08.007. [PMCID: PMC2648973] [PubMed: 18243889] [CrossRef: 10.1016/j.comppsy.2007.08.007]
9. Keitner GI, Ryan CE, Miller IW, Kohn R, Bishop DS, Epstein NB. Role of the family in recovery and major depression. *Am J Psychiatry*. 1995;152(7):1002–1008. doi: 10.1176/ajp.152.7.1002. [PubMed: 7793434] [CrossRef: 10.1176/ajp.152.7.1002]
10. Kohn R. *Treatment Gap in the Americas*. Washington, DC: Pan American Health Organization; 2013. [Accessed 25 July 2018]. Available from: <https://www.paho.org/hq/dmdocuments/2013/TGap-in-the-Americas-Final-Vesion.pdf>.
11. Kohn R, Levav I, de Almeida JM, Vicente B, Andrade L, Caraveo-Anduaga JJ, et al. Los trastornos mentales en América Latina y el Caribe: asunto prioritario para la salud pública. *Rev Panam Salud Publica*. 2005;18(4–5):229–240. [PubMed: 16354419]
12. Razzouk D, Zorzetto R, Dubugras MT, Gerolin J, Mari Jde J. Leading countries in mental health research in Latin America and the Caribbean. *Rev Bras Psiquiatr*. 2007;29(2):118–122. [PubMed: 17647304]
13. Whiteford HA, Ferrari AJ, Degenhardt L, Feigin V, Vos T. The global burden of mental, neurological and substance use disorders: an analysis from the Global Burden of Disease Study 2010. *PLoS One*. 2015;10(2):e0116820. doi: 10.1371/journal.pone.0116820. [PMCID: PMC4320057] [PubMed: 25658103] [CrossRef: 10.1371/journal.pone.0116820]

14. Kessler RC, Haro JM, Heeringa SG, Pennell BE, Ustün TB. The World Health Organization World Mental Health Survey Initiative. *Epidemiol Psichiatr Soc.* 2006;15(3):161–166. [PubMed: 17128617]
15. World Health Organization. *Mental Health Atlas*. Geneva: WHO; 2017. [Accessed 25 July 2018]. Available from: http://www.who.int/mental_health/evidence/atlas/mental_health_atlas_2017/en/
16. World Health Organization *Mental health atlas-2014 country profiles*. [Accessed 25 July 2018]. Available from: http://www.who.int/mental_health/evidence/atlas/mental_health_atlas_2014/en/
17. Saxena S, Lora A, van Ommeren M, Barrett T, Morris J, Saraceno B. WHO's Assessment Instrument for Mental Health Systems: collecting essential information for policy and service delivery. *Psychiatr Serv.* 2007;58(6):816–821. doi: 10.1176/ps.2007.58.6.816. [PubMed: 17535942] [CrossRef: 10.1176/ps.2007.58.6.816]
18. Whiteford H, Ferrari A, Degenhardt L. Global Burden of Disease Studies: implications for mental and substance use disorders. *Health Aff (Millwood)* 2016;35(6):1114–1120. doi: 10.1377/hlthaff.2016.0082. [PubMed: 27269030] [CrossRef: 10.1377/hlthaff.2016.0082]
19. Institute of Health Metrics and Evaluation *Country data 2106*. [Accessed 25 July 2018]. Available from: <http://www.healthdata.org>.
20. Robins LN, Wing J, Wittchen HU, Helzer JE, Babor TF, Burke J, et al. The Composite International Diagnostic Interview: an epidemiologic instrument suitable for use in conjunction with different diagnostic systems and in different cultures. *Arch Gen Psychiatry.* 1988;45(12):1069–1077. [PubMed: 2848472]
21. Shaffer D, Fisher P, Lucas CP, Dulcan MK, Schwab-Stone ME. NIMH Diagnostic Interview Schedule for Children Version IV (NIMH DISC-IV): description, differences from previous versions, and reliability of some common diagnoses. *J Am Acad Child Adolesc Psychiatry.* 2000;39(1):28–38. doi: 10.1097/00004583-200001000-00014. [PubMed: 10638065] [CrossRef: 10.1097/00004583-200001000-00014]
22. Stagnaro JC, Cía AH, Aguilar Gaxiola S, Vázquez N, Sustas S, Benjet C, et al. Twelve-month prevalence rates of mental disorders and service use in the Argentinean Study of Mental Health Epidemiology. *Soc Psychiatry Psychiatr Epidemiol.* 2018;53(2):121–129. doi: 10.1007/s00127-017-1475-9. [PubMed: 29302708] [CrossRef: 10.1007/s00127-017-1475-9]
23. Andrade LH, Wang YP, Andreoni S, Silveira CM, Alexandrino-Silva C, Siu ER, et al. Mental disorders in megacities: findings from the São Paulo megacity mental health survey, Brazil. *PLoS One.* 2012;7(2):e31879. doi: 10.1371/journal.pone.0031879. [PMCID: PMC3279422] [PubMed: 22348135] [CrossRef: 10.1371/journal.pone.0031879]
24. Posada-Villa JA, Aguilar-Gaxiola SA, Magaña CG, Gómez LC. Prevalencia de trastornos mentales y uso de servicios: resultados preliminares del Estudio nacional de salud mental. Colombia, 2003. *Rev Colomb Psiquiatr.* 2004;33(3):241–262.
25. Medina-Mora ME, Borges G, Lara C, Benjet C, Blanco J, Fleiz C, et al. Prevalence, service use, and demographic correlates of 12-month DSM-IV psychiatric disorders in Mexico: results from the Mexican National Comorbidity Survey. *Psychol Med.* 2005;35(12):1773–1783. doi: 10.1017/S0033291705005672. [PubMed: 16300691] [CrossRef: 10.1017/S0033291705005672]
26. Piazza M, Fiestas F. Prevalencia anual de trastornos y uso de servicios de salud mental en el Perú: Resultados del estudio mundial de salud mental, 2005. *Rev Peru Med Exp Salud Publica.* 2014;31(1):30–38. [PubMed: 24718524]
27. Wang PS, Lane M, Olfson M, Pincus HA, Wells KB, Kessler RC. Twelve-month use of mental health services in the United States: results from the National Comorbidity Survey Replication. *Arch Gen Psychiatry.* 2005;62(6):629–640. doi: 10.1001/archpsyc.62.6.629. [PubMed: 15939840] [CrossRef: 10.1001/archpsyc.62.6.629]

28. Gravel R, Béland Y. The Canadian Community Health Survey: mental health and well-being. *Can J Psychiatry*. 2005;50(10):573–579. doi: 10.1177/070674370505001002. [PubMed: 16276847] [CrossRef: 10.1177/070674370505001002]
29. Saldivia S, Vicente B, Kohn R, Rioseco P, Torres S. Use of mental health services in Chile. *Psychiatr Serv*. 2004;55(1):71–76. doi: 10.1176/appi.ps.55.1.71. [PubMed: 14699204] [CrossRef: 10.1176/appi.ps.55.1.71]
30. Puac-Polanco VD, Lopez-Soto VA, Kohn R, Xie D, Richmond TS, Branas CC. Previous violent events and mental health outcomes in Guatemala. *Am J Public Health*. 2015;105(4):764–771. doi: 10.2105/AJPH.2014.302328. [PMCID: PMC4358168] [PubMed: 25713973] [CrossRef: 10.2105/AJPH.2014.302328]
31. Scott KM, De Jonghe P, Stein DJ, Kessler RC. *Mental Disorders Around the World: Facts and Figures from the WHO World Mental Health Surveys*. Cambridge, UK: Cambridge University Press; 2018.
32. Andrade L, Caraveo-Anduaga JJ, Berglund P, Bijl RV, De Graaf R, Vollebergh W, et al. The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys. *Int J Methods Psychiatr Res*. 2003;12(1):3–21. [PMCID: PMC6878531] [PubMed: 12830306]
33. Vicente B, Saldivia S, de la Barra F, Kohn R, Pihan R, Valdivia M, et al. Prevalence of child and adolescent mental disorders in Chile: a community epidemiological study. *J Child Psychol Psychiatry*. 2012;53(10):1026–1035. doi: 10.1111/j.1469-7610.2012.02566.x. [PubMed: 22646991] [CrossRef: 10.1111/j.1469-7610.2012.02566.x]
34. Vicente B, Saldivia S, de la Barra F, Melipillán R, Valdavia M, Kohn R. Salud mental infanto-juvenil en Chile y brechas de atención sanitarias. *Rev Med Chile*. 2012;140(4):447–457. doi: 10.4067/S0034-98872012000400005. [PubMed: 22854690] [CrossRef: 10.4067/S0034-98872012000400005]
35. Shaffer D, Gould MS, Brasic J, Ambrosini P, Fisher P, Bird H, et al. Children's Global Assessment Scale (CGAS) *Arch Gen Psychiatry*. 1983;40(11):1228–1231. [PubMed: 6639293]
36. Canino G, Shrout PE, Rubio-Stipec M, Bird HR, Bravo M, Ramirez R, et al. The DSM-IV rates of child and adolescent disorders in Puerto Rico: prevalence, correlates, service use, and the effects of impairment. *Arch Gen Psychiatry*. 2004;61(1):85–93. doi: 10.1001/archpsyc.61.1.85. [PubMed: 14706947] [CrossRef: 10.1001/archpsyc.61.1.85]
37. Benjet C, Borges G, Medina-Mora ME, Zambrano J, Aguilar-Gaxiola S. Youth mental health in a populous city of the developing world: results from the Mexican Adolescent Mental Health Survey. *J Child Psychol Psychiatry*. 2009;50(4):386–395. doi: 10.1111/j.1469-7610.2008.01962.x. [PubMed: 19040499] [CrossRef: 10.1111/j.1469-7610.2008.01962.x]
38. Kessler RC, Avenevoli S, Costello EJ, Georgiades K, Green JG, Gruber MJ, et al. Prevalence, persistence, and sociodemographic correlates of DSM-IV disorders in the National Comorbidity Survey Replication Adolescent Supplement. *Arch Gen Psychiatry*. 2012;69(4):372–380. doi: 10.1001/archgenpsychiatry.2011.160. [PMCID: PMC3445020] [PubMed: 22147808] [CrossRef: 10.1001/archgenpsychiatry.2011.160]
39. Kessler RC, Avenevoli S, Costello J, Green JG, Gruber MJ, McLaughlin KA, et al. Severity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication Adolescent Supplement. *Arch Gen Psychiatry*. 2012;69(4):381–389. doi: 10.1001/archgenpsychiatry.2011.1603. [PMCID: PMC3522117] [PubMed: 22474106] [CrossRef: 10.1001/archgenpsychiatry.2011.1603]
40. Merikangas KR, He JP, Burstein M, Swendsen J, Avenevoli S, Case B, et al. Service utilization for lifetime mental disorders in U.S. adolescents: results of the National Comorbidity Survey-Adolescent Supplement (NCS-A) *J Am Acad Child Adolesc Psychiatry*. 2011;50(1):32–45. doi: 10.1016/j.jaac.2010.10.006. [PMCID: PMC4408275] [PubMed: 21156268] [CrossRef: 10.1016/j.jaac.2010.10.006]

41. Beals J, Novins DK, Whitesell NR, Spicer P, Mitchell CM, Manson SM. Prevalence of mental disorders and utilization of mental health services in two American Indian reservation populations: mental health disparities in a national context. *Am J Psychiatry*. 2005;162(9):1723–1732. doi: 10.1176/appi.ajp.162.9.1723. [PubMed: 16135633] [CrossRef: 10.1176/appi.ajp.162.9.1723]
42. Brave Heart MY, Lewis-Fernández R, Beals J, Hasin DS, Sugaya L, Wang S, et al. Psychiatric disorders and mental health treatment in American Indians and Alaska Natives: results of the National Epidemiologic Survey on Alcohol and Related Conditions. *Soc Psychiatry Psychiatr Epidemiol*. 2016;51(7):1033–1046. doi: 10.1007/s00127-016-1225-4. [PMCID: PMC4947559] [PubMed: 27138948] [CrossRef: 10.1007/s00127-016-1225-4]
43. Vicente B, Kohn R, Rioseco P, Saldivia S, Torres S. Psychiatric disorders among the Mapuche in Chile. *Int J Soc Psychiatry*. 2005;51(2):119–127. doi: 10.1177/0020764005056759. [PubMed: 16048241] [CrossRef: 10.1177/0020764005056759]
44. Hodgkin D, Piazza M, Crisante M, Gallo C, Fiestas F. Disponibilidad de medicamentos psicotrópicos en establecimientos del Ministerio de Salud del Perú, 2011. *Rev Peru Med Exp Salud Publica*. 2014;31(4):660–668. [PubMed: 25597715]
45. Espinola-Nadurille M, Vargas Huicochea I, Raviola G, Ramirez-Bermudez J, Kutcher S. Mental health care reforms in Latin America: child and adolescent mental health services in Mexico. *Psychiatr Serv*. 2010 May;61(5):443–445. doi: 10.1176/ps.2010.61.5.443. [PubMed: 20439361] [CrossRef: 10.1176/ps.2010.61.5.443]
46. Caqueo-Urizar A, Boyer L, Gilman SE. Needs of patients with schizophrenia among an ethnic minority group in Latin America. *J Immigr Minor Health*. 2017;19(3):606–615. doi: 10.1007/s10903-016-0376-4. [PMCID: PMC6295416] [PubMed: 26936764] [CrossRef: 10.1007/s10903-016-0376-4]
47. Minoletti A, Galea S, Susser E. Community mental health services in Latin America for people with severe mental disorders. *Public Health Rev*. 2012;34(2) [PMCID: PMC4203441] [PubMed: 25339792]
48. Pan American Health Organization . *53rd Directing Council 66th Session of the Regional Committee of WHO for the Americas*. Washington, DC: PAHO; 2014. [Accessed 25 July 2018]. Plan of Action on Mental Health 2015–2020. Available from: <https://www.paho.org/hq/dmdocuments/2015/plan-of-action-on-MH-2014.pdf>.
49. World Health Organization . *Mental Health Action Plan 2013–2020*. Geneva: WHO; 2013. [2013 Accessed 25 July 2018]. Available from: http://www.who.int/mental_health/publications/action_plan/en/
50. Caldas de Almeida JM. Mental health services development in Latin America and the Caribbean: achievements, barriers and facilitating factors. *Int Health*. 2013;5(1):15–18. [PubMed: 24029840]
51. Uribe-Restrepo JM, Escobar ML, Cubillos L. Psychiatric rehabilitation in Latin America: challenges and opportunities. *Epidemiol Psychiatr Sci*. 2017;26(3):211–215. doi: 10.1093/inthealth/ihs013. [PMCID: PMC6998638] [PubMed: 27852345] [CrossRef: 10.1093/inthealth/ihs013]
52. Razzouk D, Gregório G, Antunes R, Mari JD. Lessons learned in developing community mental health care in Latin American and Caribbean countries. *World Psychiatry*. 2012;11(3):191–195. [PMCID: PMC3449352] [PubMed: 23024680]
53. Araya R, Alvarado R, Minoletti A. Chile: an ongoing mental health revolution. *Lancet*. 2009;374(9690):597–598. doi: 10.1016/S0140-6736(09)61490-2. [PubMed: 19699997] [CrossRef: 10.1016/S0140-6736(09)61490-2]
54. Levav I, Kohn R, Montoya I, Palacio C, Rozic P, Solano I, et al. Training Latin American primary care physicians in the WPA module on depression: results of a multicenter trial. *Psychol Med*. 2005;35(1):35–45. [PMCID: PMC2723767] [PubMed: 15842027]

55. Markkula N, Zitko P, Peña S, Margozzini P, Retamal C P. Prevalence, trends, correlates and treatment of depression in Chile in 2003 to 2010. *Soc Psychiatry Psychiatr Epidemiol.* 2017;52(4):399–409. doi: 10.1007/s00127-017-1346-4. [PubMed: 28197670] [CrossRef: 10.1007/s00127-017-1346-4]

Figures and Tables

TABLE 1

Global Burden of Disease 2016: percentage of Disability Adjusted Life Years (DALYs) and Years Lived with Disability (YLDs) due to mental and substance use disorders

	DALYs				YLDs			
	0–14	15–59	60+	All ages	0–14	15–59	60+	All ages
Both sexes								
Americas	5.2	16.6	3.6	10.5	17.2	28.5	9.6	22.0
North America	10.4	22.0	3.8	12.9	22.2	32.2	9.4	23.3
Latin America and the Caribbean	4.0	13.2	3.5	8.9	15.3	25.8	10.0	20.9
Mesoamerica	3.5	12.4	3.2	8.1	15.0	24.0	9.1	19.5
South America	4.8	14.1	3.6	9.4	16.3	26.9	10.4	21.8
Non-Latin Caribbean	3.5	11.1	2.8	7.2	13.0	23.8	9.4	19.0
Female								
Americas	5.3	18.1	4.0	11.1	16.0	26.8	9.9	20.9
North America	10.9	22.5	4.1	13.0	21.9	30.1	9.6	22.1
Latin America and the Caribbean	4.0	15.2	3.8	9.6	13.7	24.4	10.3	19.9
Mesoamerica	3.3	13.1	3.3	8.2	12.8	22.1	9.3	18.1
South America	5.0	16.8	4.1	10.7	15.2	26.0	10.8	21.1
Non-Latin Caribbean	3.4	12.7	3.2	8.0	11.5	22.9	9.8	18.3
Male								
Americas	5.1	15.4	3.3	10.0	18.5	30.5	9.3	23.3
North America	10.0	21.6	3.5	12.7	22.5	34.8	9.1	24.7
Latin America and the Caribbean	4.0	11.9	3.2	8.2	16.9	27.4	9.6	22.1
Mesoamerica	3.6	11.8	3.2	8/0	17.1	26.3	9.0	21.2
South America	4.6	12.1	3.1	8.5	17.4	27.9	9.8	22.6
Non-Latin Caribbean	3.5	9.9	2.5	6.6	14.6	24.9	9.0	19.7

Source: Prepared by the authors from the study results using data from the Institute of Health Metrics and Evaluation.

TABLE 2

Twelve-month prevalence of mental disorders in studies that have service utilization data

Disorder	Argentina WMHS	Brazil WMHS	Canada CCHS	Chile CPPS	Colombia WMHS	Guatemala CIDI	Mexico WMHS	Peru WMHS	USA NCS-R
Field work	2015	2005– 2008	2002	1992– 1999	2003	2009	2001– 2002	2004– 2005	2001– 2003
Age	18 ≥	18 ≥	15 ≥	15 ≥	18–65	18–65	18–65	18–65	18 ≥
Sample size	3 927	5 037	38 492	2 978	4 426	1 452	5 782	3 930	9 282
Diagnosis	DSM-IV	DSM-IV	DSM-IV	DSM-III- R	DSM-IV	DSM-IV	DSM-IV	DSM-IV	DSM-IV
Anxiety disorders	9.4	19.9	4.7	9.3	14.4	2.1	6.6	7.9	18.1
Affective disorders	5.7	11.0	5.2	9.9	7.0	1.4	4.8	3.5	9.5
Substance use disorders	2.4	3.6	11.0	10.4	2.8	3.0	2.5	1.7	3.8
Any	14.8	29.6	18.7	17.0	21.0	7.2	12.1	13.5	26.2
Severe	3.7	10.0	4.4	6.9	4.9	2.0	3.7	2.3	5.8
Moderate	5.3	9.8	6.0	6.9	8.6	1.1	3.5	5.6	9.8
Mild	5.8	9.8	8.3	3.2	7.5	4.1	4.9	5.6	10.5

Source: Prepared by the authors from the study results and in part from the following references 22 – 27.

CIDI, Composite International Diagnostic Interview; CCHS', Canadian Community Health Survey; CPPS, Chile Psychiatric Prevalence Survey; DSM, Diagnostic and Statistical Manual of Mental Disorders; NCS-R, National Comorbidity Survey-Revised; WMHS, World Mental Health Survey

TABLE 3

Twelve-month prevalence of mental disorders by regions

Disorder	Americas	North America	Latin America	Mesoamerica	South America
Weighted mean					
Anxiety disorders	14.7	16.7	13.2	6.1	16.2
Affective disorders	8.3	9.1	7.7	4.4	9.0
Substance use disorders	3.8	4.5	3.2	2.6	3.5
Any	22.7	25.4	20.7	11.5	24.4
Severe	6.1	5.7	6.4	3.5	7.6
Moderate	8.0	9.4	7.0	3.2	8.5
Mild	8.5	10.3	7.2	4.8	8.3
Mean					
Anxiety disorders	10.3	11.4	9.9	4.4	12.2
Affective disorders	6.4	7.4	6.2	3.1	7.4
Substance use disorders	4.6	7.4	3.8	2.8	4.2
Any	17.8	22.5	16.5	9.7	19.2
Severe	4.9	5.1	4.8	2.9	5.6
Moderate	6.3	7.9	5.8	2.3	7.2
Mild	6.6	9.4	5.8	4.5	6.4
Median					
Anxiety disorders	9.3	11.4	9.3	4.4	9.4
Affective disorders	5.7	7.4	5.7	3.1	7.0
Substance use disorders	3.0	7.4	2.8	2.8	2.8
Any	17	22.5	14.8	9.7	17.0
Severe	4.4	5.1	3.7	2.9	4.9
Moderate	6.0	7.9	5.6	2.3	6.9
Mild	5.8	9.4	5.6	4.5	5.8

Source: Prepared by the authors from the study results.

TABLE 4

Percent utilizing mental health services by severity of mental disorders and type of service provider

Country	Total	Any disorder	Severe	Moderate	Mild	No disorder
Argentina-WMHS						
General medical	3.8	11.2	10.8	10.5	12.3	2.4
Mental health	8.0	18.2	21.5	23.5	11.3	6.2
Any health care	10.9	26.3	27.8	31.3	21.0	8.2
Non-health care	1.7	3.3	4.2	2.2	3.7	1.4
Any treatment	11.6	27.8	30.2	32.5	22.1	8.7
Brazil-WMHS						
General medical	3.3	8.6	12.0	7.7	5.9	1.1
Mental health	5.6	14.0	23.2	12.3	6.4	2.0
Any health care	8.0	19.7	30.2	17.2	11.6	3.0
Non-health care	2.0	5.2	9.5	4.6	1.5	0.7
Any treatment	9.0	21.9	32.8	20.0	12.7	3.6
Canada-CCHS						
General medical	5.4	17.5	42.0	17.7	4.6	2.8
Mental health	5.4	16.4	40.3	16.6	4.0	3.0
Any health care	8.3	24.1	55.5	2.5	7.5	4.8
Non-health care	2.9	7.6	18.8	7.0	2.2	1.8
Any treatment	9.5	25.9	58.0	27.1	8.5	5.8
Chile-CPPS						
General medical	17.7	34.1	57.5	41.9	17.4	12.9
Mental health	5.6	13.1	29.4	9.6	5.0	3.5
Any health care	20.1	38.5	65.0	44.3	20.3	14.8
Non-health care	1.2	2.7	1.0	4.8	3.1	0.8
Any treatment	20.1	38.5	65.0	44.3	20.3	14.8
Colombia-WMHS						
General medical	2.3	6.0	9.3	6.1	2.7	1.4
Mental health	3.0	7.7	27.8	10.3	7.8	3.4
Any health care	5.0	13.2	25.7	11.5	8.4	3.0
Non-health care	0.7	1.7	4.6	0.8	0.4	0.5

Source: Prepared by the authors from the study results and in part from the following references [22](#) – [27](#).

CIDI, Composite International Diagnostic Interview; CCHS, Canadian Community Health Survey; CPPS, Chile Psychiatric Prevalence Survey; NCS-R, National Comorbidity Survey-Revised; WMHS, World Mental Health Survey

TABLE 5

Treatment gap by mental disorder and by severity

Country/Region	Anxiety disorders	Affective disorders	Substance use disorders	Any disorder	Severe	Moderate	Mild	Severe-Moderate
Country								
Argentina-WMHS	70.0			72.2	69.8	67.5	77.9	68.4
Brazil-WMHS	77.0	63.6	81.4	78.1	67.2	80.0	86.3	73.5
Canada-CCHS	69.4	58.9	76.2	74.1	42.0	72.9	91.5	60.0
Chile-CPPS	39.0	50.0	74.5	61.5	39.8	52.0	60.6	45.3
Colombia-WMHS	82.4	84.8	92.5	86.1	72.2	89.4	91.8	83.2
Guatemala-CIDI	97.1	95.1	97.0	84.9	86.9	80.9	82.9	84.8
Mexico-WMHS	77.8	86.8	82.9	81.4	76.2	79.2	87.4	77.9
Peru-WMHS	81.2	72.5	87.2	79.9	67.2	81.9	84.6	77.2
USA-NCS-R	43.6	57.8	61.9	58.9	40.3	60.1	73.8	52.4
Americas								
Weighted mean	63.9	66.7	74.7	71.2	57.6	71.5	81.2	65.7
Mean	70.8	71.2	81.7	75.2	62.4	73.8	81.9	69.2
Median	77.0	68.1	82.2	78.1	67.2	79.2	84.6	73.5
Prevalence	9.4	5.5	2.8	16.2	3.5	5.7	6.9	
North America								
Weighted mean	56.5	58.4	69.1	60.4	40.5	61.4	75.6	53.2
Mean	46.2	57.9	63.3	66.5	41.2	66.5	82.7	56.2
Prevalence	9.4	5.3	3.1	15.3	2.3	5.8	7.8	
Latin America								
Weighted mean	76.7	73.7	83.7	79.0	69.9	78.7	85.9	74.7

Source: Prepared by the authors from the study results

CIDI, Composite International Diagnostic Interview; CCHS, Canadian Community Health Survey; CPPS, Chile Psychiatric Prevalence Survey; NCS-R, National Comorbidity Survey-Revised; WMHS, World Mental Health Survey